Ticker News
$CRIS News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
Curis prices ~$8.5M private placement of 16.7M units with $0.60 warrants
Curis announced a private placement of 16,666,680 common shares (or pre-funded warrants in lieu) plus common warrants to purchase up to 16,666,680 shares at a combined effective price of $0.51 per unit, expected to raise approximately $8.5M before fees. The common warrants carry a $0.60 exercise price, are exercisable six months after issuance (expire 5.5 years after issuance), and pre-funded warrants have a $0.01 exercise price and are exercisable immediately; the offering is expected to close on or about October 19, 2026. The company also agreed to amend existing warrants (1,126,676 January-2026 warrants and 3,733,334 August-2026 warrants) to a reduced $0.60 exercise price, creating additional potential future dilution of up to 4,860,010 shares. Timing: The press release does not indicate dilution today. Earliest dilution: Oct 19, 2026 settlement. Earliest dilution: Oct 19, 2026 settlement.
Curis prices $5.6M registered offering: 3.733M shares (or pre-funded) + 3.733M warrants at $1.50/unit
Curis priced a registered public offering of 3,733,334 common shares (or pre-funded warrants in lieu) with accompanying common warrants to purchase up to 3,733,334 shares at a combined price of $1.50 per share-plus-warrant (or $1.49 per pre-funded-warrant-plus-warrant). Gross proceeds are expected to be approximately $5.6 million before fees; A.G.P./Alliance Global Partners is lead placement agent and the offering is expected to close on or about August 14, 2026. The common warrants carry a $1.75 exercise price, are exercisable immediately and expire in five years; pre-funded warrants have a $0.01 exercise price and are immediately exercisable. Timing: The press release does not indicate dilution today; initial share dilution occurs at the offering close (Aug 14, 2026), and once the offering closes those shares have been issued.
CRIS: First six patients consented in TakeAim CLL; initial data due Dec 2026
Curis (CRIS) said it has consented the first six patients in its TakeAim CLL Phase 2 study of emavusertib plus zanubrutinib, expects to dose five CLL patients by end-July 2026 and plans to report initial CLL data in December 2026. The open-label trial enrolls MRD+ CLL patients already on zanubrutinib to test whether adding emavusertib (IRAK4/TLR pathway inhibitor) to a BTK inhibitor produces deeper responses (e.g., CR or undetectable MRD) versus BTKi alone.